EU Launches Joint Scientific Consultations to E...

By João L. Carapinha

January 14, 2026

Launching Joint Scientific Consultations in 2026 The European Commission has initiated the first submission period for Joint Scientific Consultations under the EU Health Technology As...
NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leuka...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fa...
NICE HealthTech Methods Update
Global Health Technology Assessment: Navigating NICE’s Role and Challen...
Revolutionizing Pharmacoeconomic Evaluations Nederland: Zorginstituut’s...
NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patie...
Talquetamab Multiple Myeloma: Impact, Evidence, and Policy Considerations
NICE Rejects Donanemab: Treatment Cost-Effectiveness
Blinatumomab Benefit Assessment for ALL and Health Economics
NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global He...
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...